ChemicalBook > Product Catalog >API >Nervous system drugs >Antiepileptic and anticonvulsant >Pregabalin


Pregabalin Suppliers list
Company Name: Kono Chem Co., Ltd
Tel: +86-132 8924 6953
Products Intro: Product Name:Pregabalin
Purity:99% Package:1g;25g;1kg;25kg;100kg Remarks:Pharmaceutical grade
Company Name: Hebei Guanlang Biotechnology Co., Ltd.
Tel: +86-0311-66562153 whatsapp +8615203118427
Products Intro: Product Name:Pregabalin
Purity:99% Package:25kg
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Products Intro: Product Name:(S)-3-(aminomethyl)-5-methylhexanoic acid
Purity:98%(Min.HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Products Intro: Product Name:Pregabalin
Purity:99% Package:846/KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Pregabalin
Purity:99% Package:100g,500g,1KG,10KG,100KG

Lastest Price from Pregabalin manufacturers

  • Pregabalin
  • US $7.00 / kg
  • 2018-12-19
  • CAS: 148553-50-8
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
  • Pregabalin
  • US $150.00 / KG
  • 2018-07-26
  • CAS:148553-50-8
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 200KG
Pregabalin Basic information
Description Generic formulation Indications Dose titration Plasma levels monitoring Antiepileptic drus and therapeutic drugs for neuropathic pain Cautions Adverse effects Interactions Special populations Behavioural and cognitive effects in patients with epilepsy Psychiatric use
Product Name:Pregabalin
Synonyms:Pregabalin SynonyMs 3-(AMinoMethyl)-5-Methyl-hexanoic acid;Pregabalin 3-(Aminomethyl)-5-methyl-hexanoic acid;Pregabalin solution;Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-;Pregabalin and Intermediates;Pregabaline whatsapp;优质 血球蛋白粉 厂家直销 血球蛋白粉 是具有血制品特殊气味的暗红或类红色的均匀粉末,无腐败变质异味,不得含有植物性物质。 血球蛋白粉的特点是: 1. 高蛋白质,高赖氨酸,高缬氨酸。 它经国家权威机构抽样检测显示,血球蛋白粉粗蛋白质含量高达88%以上,其中赖氨酸和缬氨酸分别高达7.4%和7.5%,丰富的 必需氨基酸对母猪泌乳性能有很大的促进作用。 2. 丰富的优质有机铁。 富含250;(S)-3-(Aminomethyl)-5-methylhexanoic acid (Pregabalin)
Product Categories:Pregabaline whatsapp;8618031153937;APIs;Miscellaneous Biochemicals;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;API;Pfizer compounds;LYRICA
Mol File:148553-50-8.mol
Pregabalin Structure
Pregabalin Chemical Properties
Melting point 194-196°C
alpha D23 +10.52° (c = 1.06 in water)
Fp 9℃
storage temp. Store at RT
solubility deionized water: ≥10mg/mL
form white powder
CAS DataBase Reference148553-50-8(CAS DataBase Reference)
Safety Information
Hazard Codes Xn,T,F
Risk Statements 63-48/22-39/23/24/25-23/24/25-11
Safety Statements 22-36/37-45-16-7
RIDADR UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany 3
HS Code 29224999
Hazardous Substances Data148553-50-8(Hazardous Substances Data)
MSDS Information
Pregabalin Usage And Synthesis
DescriptionPregabalin is a second- generation antiepileptic drug (AED) known with the proprietary brand name of Lyrica® (Pfizer, Tadworth) in the UK and USA (Pfizer, New York, NY).
Generic formulationMHRA/ CHM advice to minimize risk when switching patients with epilepsy between different manufacturers’ products (including generic products):
  • It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns, such as patient anxiety and risk of confusion/ dosing error.
Adjunctive therapy of focal seizures with and without secondary generalization.

Recommendations summarized from NICE (2012)
  • Seizure types—on referral to tertiary care (focal seizures), contraindicated (generalized tonic- clonic seizures, tonic/ atonic seizures, absence seizures, myoclonic seizures).
  • Epilepsy types—on referral to tertiary care (benign epilepsy with centrotemporal spikes, panayiotopoulos syndrome, late- onset childhood occipital epilepsy), contraindicated (absence syndromes, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, Dravet syndrome, Lennox– Gastaut syndrome).

Generalized anxiety disorder.

Peripheral and central neuropathic pain.
Dose titration
  • Epilepsy— adjunctive therapy: 25 mg bd for 7 days, to be increased by 50 mg every 7days; usual maintenance 300 mg daily, divided into 2 or 3 doses (max. 600 mg daily, divided into 2 or 3 doses).
  • Generalized anxiety disorder: 150 mg daily, divided into 2 or 3 doses, for 7 days, to be increased by 150 mg every 7 days (max. 600 mg daily, divided into 2 or 3 doses).
If stopping pregabalin, it is recommended to taper over at least 1 week to avoid abrupt withdrawal.
Plasma levels monitoringPregabalin pharmacokinetics are linear over the recommended daily dose range; inter- subject pharmacokinetic variability for pregabalin is low (<20%) and multiple dose pharmacokinetics are predictable from single- dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.
Antiepileptic drus and therapeutic drugs for neuropathic painPregabalin is a new antiepileptic drug, having a γ-amino butyric acid structure on its molecular structure, which has anticonvulsant effects, and is successfully developed by the company Pfizer for the treatment of peripheral neuropathic pain, or adjuvant treatment of partial seizures.
In December 2008, the US Food and Drug Administration (FDA) approved pregabalin (trade name "Lyrica") for the treatment of diabetic peripheral neuropathic pain (DPN) and postherpetic neuralgia (PHN)which are Both the most common neuropathic pains.
Neuropathic pain is one of the most difficult chronic pain syndromes to treat , dull pain, burning, tingling as the main feature, there are a lot of incentives of neuralgia, diabetes, infections (such as herpes zoster), cancer and AIDS, etc. can cause neurological pain, in Europe about 3% of the population suffer from neuralgia torture.
The above information is edited by the chemicalbook of Tian Ye.
  1. Patients with conditions that may precipitate encephalopathy.
  2. Patients with severe congestive heart failure.
Adverse effectsPregabalin can be associated with adverse effects at the level of the nervous system and other systems.
  • Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans, does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce or be subject to pharmacokinetic interactions.
  • Pregabalin may potentiate the effects of lorazepam.
  • In the post- marketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other central nervous system depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
With alcohol/food
  • There are no specific foods that must be excluded from diet when taking pregabalin.
  • Pregabalin may potentiate the effects of alcohol.
Special populationsHepatic impairment
No dose adjustment is required for patients with hepatic impairment.

Renal impairment
Reduce maintenance dose according to degree of reduction in creatinine clearance.

  • There is no adequate data from the use of pregabalin in pregnant women. The potential risk for reproductive toxicity in humans is unknown. Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.
  • Pregabalin is excreted into human milk. The effect of pregabalin on newborns/ infants is unknown. A case- by- case decision must be made whether to discontinue breast- feeding or to discontinue pregabalin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Behavioural and cognitive effects in patients with epilepsyPregalin is characterized by a good behavioural profile. This AED does not appear to have significant negative effects on mood or behaviour in patients with epilepsy, although depression has been reported in some patients (dose- dependent effects of mild- to- moderate intensity). A potential abuse or misuse of pregabalin has also been reported, with implications in terms of dependence and withdrawal. pregabalin is also associated with limited negative cognitive effects, mainly related to sedation, decreased arousal, decreased attention and concentration (dose- dependent effects of mild- to- moderate intensity).
Psychiatric usePregabalin has an approved indication and is widely used for the treatment of generalized anxiety disorder. Several randomized, double- blind, placebocontrolled trials found that pregabalin is an effective treatment for patients with generalized anxiety disorder and social anxiety disorder. Possible implications in the treatment of mood disorders and benzodiazepines dependence are emerging. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention.
Chemical PropertiesOff-White Solid
UsesS-Enantiomer of Pregabalin. A GABA analogue used as an anticonvulsant. Anxiolytic analgesic used to treat peripheral neuropathic pain and fibromyalgia.
UsesPregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade nam
Brand nameLyrica (CP).
Pregabalin Preparation Products And Raw materials
Tag:Pregabalin(148553-50-8) Related Product Information
1-(2,6-Dimethylphenoxy)-2-propanamine (S)-N-Methyl Pregabalin rac Pregabalin-d7 DISCONTINUED see P704803 (+/-)-Pregabalin,RAC PREGABALIN HEXANOIC-6,6,6-D3 ACID Pregabalin 2-[[[[(4-Methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]benzoic acid methyl ester Methyl bromide Hexanoic acid 17a-Hydroxyprogesterone caproate Ethyl Hexanoate Methyl Kresoxim-methyl Methyl salicylate Parathion-methyl 6-Aminocaproic acid Allyl hexanoate Methyl acetate